6MO Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score ≥50%: KEYNOTE-598 3-year follow-up
| Autor: | Rodriguez Abreu, D., Reck, M., Şendur, N., Park, K., Lee, D.H., Cicin, I., Yumuk, P.F., Orlandi, F.J., Leal, T.A., Soparattanapaisarn, N., Langleben, A., Califano, R., Medgyasszay, B., Hsia, T-C., Otterson, G.A., Woods, T., Jensen, E., Samkari, A., Boyer, M. |
|---|---|
| Zdroj: | In Annals of Oncology April 2022 33 Supplement 2:S30-S31 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|